Revenue tied to Lilly’s Zepbound and Mounjaro more than doubles from the same period last year.

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

Eli Lilly has more to offer than some investors realize.

Eli Lilly is set to post earnings Thursday morning, with the stock seen potentially sinking to its lowest level in months ...

Eli Lilly shares jumped after the drugmaker posted earnings that topped estimates and hiked its outlook, thanks to booming ...

The American Hospital Association has called on federal regulators to intervene after Eli Lilly sent warning letters to 340B hospitals threatening to cut off discounted drug pricing unless they submit ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.

Eli Lilly beats Q1 estimates and raises 2026 revenue outlook to $82–$85 billion. Mounjaro and Zepbound drive strong sales ...

Eli Lilly (LLY 2.56%) has established itself as the leader in the weight-loss drug market. Since this area is projected to ...

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax ...